Ireland· IE-PA-PA2315/281/003
Selexipag Accord 600 microgram film-coated tablets
A selexipag product containing selexipag, registered in Ireland by Accord Healthcare Ireland Ltd.. The same ATC class is registered in 13 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Selexipag is registered in 13 of 19 countries.
Countries holding a registration under ATC B01AC27 (selexipag), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 8 of them publish a price we can compare per daily dose
Selexipag · ATC B01AC27
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of selexipag costs, country by country.
Normalised to the WHO defined daily dose (1.8 mg), the median price runs from $809.99 in Switzerland to $1232.99 in Italy — a ×1.5 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Selexipag · price per daily dose (1.8 mg)
USD · FX 28 Sept 2026
- IT Italy$1232.99
- CH Switzerland$809.99
The record
At a glance
HPRA (Ireland)- Active substance
- Selexipag
- Manufacturer
- Accord Healthcare Ireland Ltd.
- Country
- Ireland (IE)
- ATC code
- B01AC27
- ATC class
- Selexipag
- Defined daily dose
- 1.8 mg, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberPA2315/281/003
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
237 interactions on record for selexipag.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Selexipag · interactions on record
237 records
- 1 severe
- 232 moderate
- 4 minor
Most severe, free to view
- GemfibrozilC10AB04severe
- PapaverineA03AD01moderate
- MannitolA06AD16moderate
- GlycerolA06AX01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Selexipag in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsSelexipag Abdi 600 microgram filmomhulde tablettenAbdi Farma GmbH
- SwedenSelexipag Accord 600 mikrogram Filmdragerad tablettAccord Healthcare B.V.
- CzechiaSELEXIPAG ACCORDACCORD HEALTHCARE POLSKA Sp. z o.o., Varšava
- PolandSelexipag AccordAccord Healthcare Polska Sp. z o.o.
- SpainSELEXIPAG ACCORD 600 MICROGRAMOS COMPRIMIDOS RECUBIERTOS CON PELICULA EFGAccord Healthcare S.L.U.
- United StatesSelexipagZydus Lifesciences Limited
- NorwayUptraviJanssen-Cilag International N.V.
- FinlandUptraviJanssen-Cilag International NV
Authorised across Europe · EMA
The same active substance is authorised in 18 EEA countries. Names it is sold under:
- Austria · Selexipag Ratiopharm
- Cyprus · Selexipag Accord
- Denmark · Selexipag Accord, Selexipag Stada
- Estonia · Selexipag Stada
- Spain · Selexipag Accord, Selexipag Stada
- Greece · Xipeno
- Croatia · Seleksipag Accord
- Iceland · Selexipag Stada, Uptravi
- Italy · Selexipag Accord, Selexipag Eg
- Liechtenstein · Uptravi
- Lithuania · Selexipag Stada
- Latvia · Selexipag Stada
- Malta · Selexipag Clonmel
- Netherlands · Seleksipag Accord, Selexipag Abdi
- Norway · Selexipag Accord, Selexipag Stada
- Poland · Selexipag, Selexipag Accord
- Portugal · Selexipag Accord, Selexipag Teva
- Sweden · Selexipag, Selexipag Accord
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b1b353e0-46ea-411c-9542-8f8d2f8a4eb5 GET /v1/drugs/b1b353e0-46ea-411c-9542-8f8d2f8a4eb5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"B01AC27"
],
"strength": null,
"pa_number": "PA2315/281/003",
"substances": [
"Selexipag"
],
"legal_basis": "Generic application (Article 10(1) of Directive No 2001/83/EC)",
"market_info": "Not marketed",
"authorised_at": "14/11/2025",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about selexipag.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.